TerminatedPhase 3NCT01439347
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Principal Investigator
- Susan M O'Brien, MDMD Anderson
- Intervention
- Vincristine Sulfate Liposomes Injection (VSLI)(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 60 years · All sexes
- Timeline
- 2012 – 2015
Study locations (15)
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- UCLA, Los Angeles, California, United States
- Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
- Northwestern University Fienberg School of Medicine, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Nebraska Medical Center, Omaha, Nebraska, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Cornell, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
- Seattle Cancer Care Alliance, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01439347 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University